Evaluation of Blood Pressure Reduction, Safety, and Tolerability of Canagliflozin in Patients With Hypertension and Type 2 Diabetes Mellitus on Stable Doses of Anti-hyperglycemic and Anti-hypertensive Agents
A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 171 participants.
Also called NCT01939496
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 4
- Enrolled
- 171 participants
- Registry
-
NCT01939496
-
- Start date
- (registry gives no type)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States, Puerto Rico
- Registry status
- Completed
Technical summary
Registry record NCT01939496. Randomized; quadruple masking; primary purpose treatment. Start 2013-10 (registry gives no type); primary completion 2015-04 (actual). Results posted on 2016-04-06.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Evaluation of Blood Pressure Reduction, Safety, and Tolerability of Canagliflozin in Patients With Hypertension and Type 2 Diabetes Mellitus on Stable Doses of Anti-hyperglycemic and Anti-hypertensive Agents
- Condition
- Diabetes Mellitus, Type 2
- Condition
- Hypertension
- Intervention (Drug)
- Canagliflozin
- Intervention (Drug)
- Placebo
- Lead sponsor
- Janssen Scientific Affairs, LLC
Record details
- Record id
cardio:ct-nct01939496- Content hash
bc75cb672958cd6dbb554501368ca601b5b5c722b42731b01e81d2622d2e8f80